Abiozen’s CRO360™ division is at the forefront of modern clinical trial execution, utilizing cutting-edge digital technologies to decentralize trials and generate real-world evidence (RWE) that supports regulatory approvals and post-market strategy. Our hybrid models improve trial accessibility, reduce patient burden, and accelerate both enrollment and data generation—transforming traditional paradigms of drug development.

Decentralized Clinical Trials (DCTs)
Our decentralized trial infrastructure integrates telemedicine, virtual site visits, eConsent platforms, and wearable health technologies to enable remote participation without compromising data integrity. This patient-centric model improves accessibility, particularly for underrepresented populations and those in geographically dispersed regions. Our DCT approach has demonstrated a 25% improvement in recruitment rates and significantly higher retention by reducing logistical barriers to participation. Inspired by Thermo Fisher Patheon’s remote monitoring innovations, we blend digital and physical oversight to maintain compliance, safety, and engagement across all trial phases.

Real-World Evidence (RWE) for Lifecycle Extension
Beyond traditional trials, Abiozen captures and analyzes real-world data (RWD) from electronic health records, claims databases, patient registries, and wearable devices to validate treatment outcomes in everyday clinical settings. Our RWE studies support submissions for label expansions, new indications, and market access in multiple global regions. By generating insights into safety, effectiveness, adherence, and quality of life, we empower sponsors to make data-driven decisions and enhance the value proposition of their therapeutics. Our evidence-driven strategies are aligned with best practices observed in Thermo Fisher CRDMO’s RWE lifecycle management model.